Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of
quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2)
continuation effects of quetiapine XR in preventing SAD relapse.
- Adults 18-65 years of age
- A primary diagnosis of SAD,using Diagnostic Standard Manual IV(DSM-IV) criteria
- Minimum CGI severity score of 4 and minimum Brief Social Phobia Scale (BSPS) score of
20 at baseline
- Written informed consent
- A negative serum pregnancy test for women of childbearing potential.
- Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic
disorder, mental retardation or other pervasive developmental disorder, or cognitive
disorder due to a general medical condition
- Any current primary anxiety disorder other than SAD or current primary depression
- History of substance abuse or dependence within the last 6 months
- Suicide risk or serious suicide attempt within the last year
- Clinically significant medical condition or laboratory abnormality
- Women of childbearing potential who are unwilling to practice an acceptable method of
- Subjects needing concurrent use of psychotropic medications
- History of hypersensitivity to quetiapine
- History of cataracts.